Navigation Links
Discovery Labs Receives US Patent for Method to Promote Mucus Clearance with Pulmonary Surfactant
Date:7/18/2012

WARRINGTON, Pa., July 18, 2012 /PRNewswire/ -- Discovery Laboratories, Inc. (Nasdaq: DSCO) today announced it has received a patent issued by the United States Patent and Trademark Office (USPTO) entitled "Pulmonary Surfactant Formulations and Methods for Promoting Mucus Clearance."  The claims of the patent (U.S. Patent Number 8,221,772) provide coverage for a method for promoting mucus clearance in a patient with a pulmonary condition characterized by excessive mucus secretion or impaired mucus clearance such as cystic fibrosis (CF), bronchiectasis, ciliary diskinesia, chronic obstructive pulmonary disease (COPD), and sinusitis.  The patent term expires in September 2027.

"This patent enhances Discovery Labs' patent portfolio by providing protection in the area of pulmonary conditions characterized by impaired mucus clearance," said W. Thomas Amick, Chairman of the Board and Chief Executive Officer of Discovery Labs.   "Combined with Discovery Labs' proprietary aerosolization technologies, our KL4 surfactant may provide a new opportunity to develop treatments to address a number of debilitating respiratory disorders where unmet needs still persist." 

In addition to this patent, Discovery Labs also has the benefit of certain regulatory designations, including U.S. and EU Orphan Designations for the treatment of CF with KL4 surfactant, which potentially strengthen the company's exclusivity position for this indication.

ABOUT DISCOVERY LABS
Discovery Laboratories, Inc. is a specialty biotechnology company with one focus – to create life-saving products for critical care patients with respiratory disease and improve the standard of care for pulmonary medicine. Discovery Labs' novel proprietary KL4 surfactant technology produces a synthetic, peptide- containing surfactant that is structurally similar to pulmonary surfactant and is being developed in liquid, lyophilized and aerosolized formulations. Discovery Labs is also developing its proprietary drug delivery technologies to enable efficient, targeted upper-respiratory or alveolar delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs believes that its proprietary technologies make it possible, for the first time, to develop a significant pipeline of products to address a variety of respiratory diseases for which there frequently are few or no approved therapies. For more information, please visit our website at www.discoverylabs.com.

Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from the statements made. Examples of such risks and uncertainties, including those related to Discovery Labs' efforts to secure exclusivity protections for its drug and medical device products through patents and regulatory designations, are described in Discovery Labs' filings with the Securities and Exchange Commission, including the most recent reports on Forms 10-K, 10-Q and 8-K, and any amendments thereto. Any forward-looking statement in this release speaks only as of the date on which it is made. Discovery Labs assumes no obligation to update or revise any forward-looking statements.


'/>"/>
SOURCE Discovery Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Protein and Peptide-based Therapeutics - Trends in Drug Discovery and Development
2. Global Information, Inc. Announces New Market Forecasts For Drug Discovery Industry as it Emerges from Recession
3. Tetra Discovery Partners Receives Major NIH Award To Develop New Alzheimers Drug
4. AMRI Further Expands Discovery Capabilities in India
5. Drug Discovery Technologies Market Soars to $79 billion by 2017, Driven by Innovations in Pipeline and Tools Development
6. Aethlon Medical (AEMD) Note: Cancer Research Discovery - Melanoma Exosomes Fuel Organ Metastasis
7. Dr. Paul Karila Appointed Head of Discovery Services at Cellectricon AB
8. University Hospitals Case Medical Centers Harrington Discovery Institute Launches Grant Program to Accelerate Drug Discovery and Development
9. Galenea to Receive $6 Million From The Stanley Medical Research Institute to Progress Pro-Cognitive Drug Discovery and Development Program
10. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
11. TeraDiscoveries to Use its Inverse Design Software Running on Windows Azure to Advance Its Computational Drug Discovery Process
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... RESEARCH TRIANGLE PARK, N.C. , July ... UTHR ) announced today that it will report ... opens on Thursday, July 27, 2017. ... on Thursday, July 27, 2017, at 9:00 a.m. Eastern ... international callers dialing 1-970-315-0533.  A rebroadcast of the teleconference ...
(Date:7/21/2017)... -- Did you know that PhRMA member companies invested $65.5 billion ... on brand medicines, generics and the supply chain account for 14 ... half of this (7 percent)? Or that the United ... capital investments in high-growth biopharmaceutical startups? ... The biopharmaceutical industry ...
(Date:7/19/2017)...  Mako Medical Laboratories partnered with Secretary Strickland, the ... Fund (MFA) to bring 140 soldiers back home to ... families one last time before being deployed. Mako Medical ... logistics needed for these soldiers. "Mako Medical Laboratories is ... We just wish we could bring them all home," ...
Breaking Medicine Technology:
(Date:7/24/2017)... ... July 24, 2017 , ... Cheerag D. Upadhyaya , ... Marion Bloch Neuroscience Institute (SLMBNI), part of Saint Luke’s Health System . ... , Cheerag D. Upadhyaya, MD. M.Sc., FAANS joins Stanley P. Fisher, M.D., ...
(Date:7/24/2017)... ... July 24, 2017 , ... Horizon Goodwill Industries, ... unique opportunity that helps high school girls succeed in STEM programs as well ... Horizon Goodwill will host over 20 high school girls at their corporate headquarters ...
(Date:7/24/2017)... ... , ... Every year, thousands of dedicated Higher Education and K12 professionals flock ... coupled with a dynamic theme like Camp Canvas; this year, they’ve managed to take ... , To extend their partnership with Canvas beyond the LMS integration, Modo Labs secured ...
(Date:7/24/2017)... ... July 24, 2017 , ... A CDC study shows that, although people are taking more ... 18 to 29), had at least one case of sunburn within the past year. It’s ... people to ignore the issue. However, only recently have people become conscientious of the risks ...
(Date:7/24/2017)... ... , ... Sharon Kleyne, host of the nationally syndicated The Sharon Kleyne Hour ... Tears® EyeMist® recently talked on the air about an alarming Post magazine article of ... Zidor Aldama described the situation in which Chinese children are under pressure to perform ...
Breaking Medicine News(10 mins):